Diversify Before The Patent Cliff
15:55–16:25 · 30s
Lou explains why Eli Lilly is racing to buy new drug pipelines now—acknowledging that most acquisitions may fail but a few winners could secure its future beyond GLP-1 hype.
15:55–16:25 · 30s
Lou explains why Eli Lilly is racing to buy new drug pipelines now—acknowledging that most acquisitions may fail but a few winners could secure its future beyond GLP-1 hype.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.